TScan Therapeutics Pauses Solid Tumor Trial to Prioritize Heme, and Extends Cash Runway into Second Half of 2027

TScan Therapeutics (TCRX) announced a major strategic shift, securing FDA alignment for its pivotal TSC-101 trial for blood cancers, improving manufacturing speed, and cutting costs to extend its financial health into the second half of 2027.